
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
This special report offers an article regarding current FDA thinking and future direction with these assessments. ERT-a cloud platform solutions provider that captures quality efficacy and safety endpoints in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment, and Clinical Outcome Assessments-offers expert view on this regulatory change.






